Emmaus Life Sciences, Inc.
EMMA
$0.07
$0.019.23%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.98% | -27.33% | -25.22% | -41.78% | -29.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.98% | -27.33% | -25.22% | -41.78% | -29.92% |
| Cost of Revenue | -7.79% | -31.57% | -28.64% | -14.04% | 19.38% |
| Gross Profit | 12.55% | -27.01% | -24.95% | -43.33% | -32.26% |
| SG&A Expenses | -27.70% | -28.28% | -33.78% | -39.53% | -28.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.18% | -30.24% | -34.10% | -38.16% | -27.32% |
| Operating Income | 518.88% | 389.55% | 112.20% | -4,147.22% | -39.41% |
| Income Before Tax | -36.75% | -93.13% | -16.49% | -103.35% | 25.24% |
| Income Tax Expenses | 202.93% | -77.50% | -68.97% | 98.88% | -1,062.00% |
| Earnings from Continuing Operations | -77.88% | -91.59% | -16.10% | -108.50% | 35.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.88% | -91.59% | -16.10% | -108.50% | 35.58% |
| EBIT | 518.88% | 389.55% | 112.20% | -4,147.22% | -39.41% |
| EBITDA | 531.87% | 486.73% | 114.42% | -1,806.10% | -41.70% |
| EPS Basic | -71.56% | -83.38% | -12.93% | -110.31% | 35.01% |
| Normalized Basic EPS | -1.57% | -118.51% | -2.74% | -66.32% | 18.68% |
| EPS Diluted | -71.97% | -86.53% | -15.06% | -99.32% | 36.07% |
| Normalized Diluted EPS | -25.85% | -118.51% | -2.74% | -66.32% | 27.05% |
| Average Basic Shares Outstanding | 5.22% | 2.95% | 1.28% | 4.59% | 9.16% |
| Average Diluted Shares Outstanding | 24.93% | 2.95% | 1.28% | 4.59% | -19.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |